Company Overview

Biofil Chemicals and Pharmaceuticals Limited is a pharmaceutical and chemical manufacturing company incorporated in 1993 and headquartered in Indore, Madhya Pradesh. Initially incorporated as a private limited company in 1985, it was converted to a public limited company in 1992. The company is listed on both the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE: 524396) and trades under the script name BIOFILCHEM.

Business Operations and Product Portfolio

Biofil Chemicals and Pharmaceuticals Limited is engaged in the manufacturing and trading of pharmaceutical products, operating through two primary segments: the Pharmaceutical Division and the Chemicals Division. The company is also involved in producing plastic products for packaging pharmaceutical and other plastic goods.

The company's diverse product portfolio is categorized into two main areas:

- Basic Drugs & Chemicals: This includes products such as Sodium Chloride, Potassium Chloride, Sodium Citrate, Diethyl Carbamazine Citrate, Ferrous Sulphate, Dried Ferrous Sulphate, Ferrous Fumerate, Micro Crystalline Cellulose, and Dicyclomine Hydrochloride.

- Pharmaceutical Formulations & Packaging: Biofil Chemicals' product range extends to dry syrups, injectables, and eye drops. Its packaging segment includes plastic droppers and caps.

Additionally, the company provides job work services for manufacturing pharmaceutical drugs. Biofil Chemicals operates manufacturing plants strategically located at Kheda Industrial Estate, Pithampur District, Dhar, and Sanwer Road, Industrial Area, Indore, in Madhya Pradesh.

Financial Performance and Market Position

As of the latest available data, Biofil Chemicals & Pharmaceuticals Ltd has a market capitalization of ₹75 crore as of May 16, 2025. According to Value Research classification, it is categorized as a Small Cap company.

Recent Quarterly Performance

The company has experienced significant fluctuations in its quarterly financial results:

- Q3 FY2024-25 (Quarter ended December 2024): Net profit saw a substantial rise of 77.78%, reaching ₹0.16 crore, up from ₹0.09 crore in Q3 FY2023-24. Sales surged by 182.31% to ₹14.20 crore, compared to ₹5.03 crore in the corresponding prior-year period.

- Q2 FY2024-25 (Quarter ended September 2024): The company faced challenges, with net profit declining by 83.33% to ₹0.02 crore, down from ₹0.12 crore in September 2023. Sales also decreased by 86.13% to ₹2.41 crore, from ₹17.37 crore in the previous year's quarter.

Key Financial Metrics

- TTM Profit: Trailing Twelve Months (TTM) profit after tax was ₹1 crore.

- Return Performance: The company has delivered a negative return of -7.74% over the last 3 years.

- Growth Metrics: Sales growth has been moderate, with an 11.6% increase over the past five years.

- Profitability: The company exhibits a low return on equity of 3.84% over the last 3 years.

Valuation Metrics

- Price-to-Book (P/B) Ratio: The P/B ratio stands at 4.05 times as of May 16, 2025, indicating a 9% premium compared to its peers' median range of 3.72 times.

- Price-to-Earnings (P/E) Ratio: The P/E ratio is 124.25 times as of May 16, 2025, which is a significant premium of 257% over its peers' median range of 34.78 times.

Financial Health and Debt Position

Biofil Chemicals & Pharmaceuticals Ltd maintains a strong balance sheet and is generally debt-free. However, the company has a high number of debtors, averaging 301 days, which could potentially impact working capital management.

Leadership and Governance

Key members of the company's leadership team include Romil Shah, Ramesh Shah, Shaila Jain, and Satish Beohar. Recent corporate governance updates include the appointment of Mr. Apoorv Jain as Company Secretary & Compliance Officer in April 2025.

Stock Performance and Trading Information

The stock has shown considerable volatility in recent periods.

- Past 6 Months: The Biofil Chemicals & Pharmaceuticals share price has decreased by 36.08%.

- Past 1 Year: The stock has decreased by 36.53%.

- 52-Week Range: The 52-week low was ₹40.4, and the 52-week high was ₹91.87.

Industry Position and Competition

Biofil Chemicals operates within the highly competitive pharmaceutical sector, where it competes with established players such as Sun Pharmaceuticals Company Ltd., CIPLA Ltd., Dr Reddy's Laboratories Ltd., and Gland Pharma Ltd. Despite being a smaller entity, the company differentiates itself by focusing on both pharmaceutical manufacturing and plastic packaging, thereby creating a diversified revenue stream.

Success in this industry hinges on rigorous regulatory compliance, consistent product quality, and cost efficiency. While Biofil Chemicals maintains its niche position in pharmaceutical and chemical manufacturing, its financial performance reflects the challenges faced by smaller companies in competing effectively against larger, more established market participants.